Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @BiosimCenter
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BiosimCenter
-
Reference-based drug pricing increased the use of lower-cost therapies, according to new study.https://bit.ly/376MaCI
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@US_FDA,#FTC pledge cooperation to boost#biosimilar competitionhttps://www.centerforbiosimilars.com/news/fda-ftc-pledge-close-cooperation-to-create-biosimilar-competition …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
European Medicines Agency OKs marketing of Ruxience
#rituximab$PFEhttps://www.centerforbiosimilars.com/news/european-medicines-agency-authorizes-marketing-of-ruxience-rituximab …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
How can value-based care embrace the possibilities of
#biosimilars?https://www.centerforbiosimilars.com/news/how-can-valuebased-care-embrace-the-possibilities-of-biosimilars …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BREAKING NEWS: Celltrion's
#Wuhan plans on hold for now amid#coronavirus outbreakhttps://www.centerforbiosimilars.com/news/celltrions-wuhan-plans-on-hold-amid-coronavirus-outbreak …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
INTERVIEW: Brian Lehman, MBA, MHA, RPh discusses impact of
#biosimilar#insulin on patient affordabilityhttps://www.centerforbiosimilars.com/interviews/brian-lehman-mba-mha-rph-impact-of-biosimilar-insulin-on-patient-affordability …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Read about revamped
@US_FDA policy for prioritizing#generic Rx apps to broaden access https://www.centerforbiosimilars.com/news/fda-revamps-policy-for-prioritizing-generic-drug-applications-in-effort-to-widen-access …pic.twitter.com/chduYocNlK
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Experts in the field of
#biosimilars wrap up their discussion by considering what must be done to educate pharmacists, nurses, and patients. https://bit.ly/37v60IxHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
What's happening in the world of
#biosimilars? Check out our top 5 news items for the weekhttps://www.centerforbiosimilars.com/news/the-top-5-biosimilars-articles-for-the-week-of-january-27 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Conference Coverage:
@CMSGov Payment Policy Plays Role in#Biosimilar Uptakehttps://www.centerforbiosimilars.com/conferences/specialty-therapies-and-biosimilars-conference/cms-payment-policy-plays-role-in-biosimilar-uptake …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
A recent paper work looked at
#secukinumab biosimilar lentivirus-based#genetherapy, which showed successful and prolonged expression of the recombinant antibody in rats.https://bit.ly/2Rv5LYnHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
A recently column looks at the global
#multiplesclerosis market from the perspective of patients and physicians; what does it mean that different regulatory bodies have different standards in place for approval?https://bit.ly/2uBiMXEHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The FDA anticipates many more gene product approvals, saying there are more than 900 investigational new drug (IND) applications for ongoing clinical studies.https://bit.ly/2O8UBqu
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Why do standards for
#biosimilar approvals differ around the world?https://www.centerforbiosimilars.com/news/commentary-questions-differing-global-standards-for-ms-biosimilar-approvals …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
From this week's Specialty Therapies and Biosimilars Congress: Originator firms are still gaming the systemhttps://www.centerforbiosimilars.com/conferences/specialty-therapies-and-biosimilars-conference/biosimilar-makers-must-plan-for-originator-firms-gaming-the-patent-system-panel-says …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
From this week's Specialty Therapies and Biosimilars Congress: Trust is key to planning your launchhttps://www.centerforbiosimilars.com/conferences/specialty-therapies-and-biosimilars-conference/trust-planning-key-to-a-successful-biosimilar-launch-panelists-say …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
From this week's Specialty Therapies and Biosimilars Congress:
@Boehringer expert shares why IPI could be a killer for new drug investmenthttps://www.centerforbiosimilars.com/conferences/specialty-therapies-and-biosimilars-conference/international-pricing-index-could-be-a-killer-for-drug-investment …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.